Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 173

The DOI matches its Crossref record.

Tumoral and Immunologic Response After Vaccination of Melanoma Patients With an ALVAC Virus Encoding MAGE Antigens Recognized by T Cells

van Baren, Nicolas, Bonnet, Marie-Claude, Dréno, Brigitte, Khammari, Amir, Dorval, Thierry, Piperno-Neumann, Sophie, Liénard, Danielle, Speiser, Daniel, Marchand, Marie, Brichard, Vincent G., Escudier, Bernard, Négrier, Sylvie, Dietrich, Pierre-Yves, Maraninchi, Dominique, Osanto, Susanne, Meyer, Ralf G., Ritter, Gerd, Moingeon, Philippe, Tartaglia, Jim, van der Bruggen, Pierre, Coulie, Pierre G., Boon, Thierry · 2005 · Journal of Clinical Oncology

Abstract

Purpose: To evaluate the toxicity, antitumoral effectiveness, and immunogenicity of repeated vaccinations with ALVAC miniMAGE-1/3, a recombinant canarypox virus containing a minigene encoding antigenic peptides MAGE-3 168-176 and MAGE-1 161-169, which are presented by HLA-A1 and B35 on tumor cells and can be recognized by cytolytic T lymphocytes (CTLs). Materials and Methods: The vaccination schedule comprised four sequential injections of the recombinant virus, followed by three booster vaccinations with the MAGE-3 168-176 and MAGE-1 161-169 peptides. The vaccines were administered, both intradermally and subcutaneously, at 3-week intervals. Results: Forty patients with advanced cancer were treated, including 37 melanoma patients. The vaccines were generally well tolerated with moderate adverse events, consisting mainly of transient inflammatory reactions at the virus injection sites. Among the 30 melanoma patients assessable for tumor response, a partial response was observed in one patient, and disease stabilization in two others. The remaining patients had progressive disease. Among the patients with stable or progressive disease, five showed evidence of tumor regression. A CTL response against the MAGE-3 vaccine antigen was detected in three of four patients with tumor regression, and in only one of 11 patients without regression. Conclusion: Repeated vaccination with ALVAC miniMAGE-1/3 is associated with tumor regression and with a detectable CTL response in a minority of melanoma patients. There is a significant correlation between tumor regression and CTL response. The contribution of vaccine-induced CTL in the tumor regression process is discussed in view of the immunologic events that could be analyzed in detail in one patient.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2005.08.375

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 173

Metadata

Authors
van Baren, N., Bonnet, M.-C., Dréno, B., Khammari, A., Dorval, T., Piperno-Neumann, S., Liénard, D., Speiser, D., Marchand, M., Brichard, V. G., Escudier, B., Négrier, S., Dietrich, P.-Y., Maraninchi, D., Osanto, S., Meyer, R. G., Ritter, G., Moingeon, P., Tartaglia, J., van der Bruggen, P., Coulie, P. G., & Boon, T.
Venue
Journal of Clinical Oncology
Published
2005-12-10
Volume
23
Issue
35
Pages
9008-9021
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2169625332
Cited by
173
References
0
FWCI
5.47
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tumoral and Immunologic Response After Vaccination of Melanoma Patients With an ALVAC Virus Encoding MAGE Antigens Recognized by T Cells. https://app.cochat.ai/papers/10.1200/jco.2005.08.375
The paper
van Baren, N., Bonnet, M.-C., Dréno, B., Khammari, A., Dorval, T., Piperno-Neumann, S., Liénard, D., Speiser, D., Marchand, M., Brichard, V. G., Escudier, B., Négrier, S., Dietrich, P.-Y., Maraninchi, D., Osanto, S., Meyer, R. G., Ritter, G., Moingeon, P., Tartaglia, J., . . . Boon, T. (2005). Tumoral and Immunologic Response After Vaccination of Melanoma Patients With an ALVAC Virus Encoding MAGE Antigens Recognized by T Cells. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2005.08.375

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.